Using ICH Concepts to Argue for Flexible, Risk-Based Approaches with Agencies Using ICH Concepts to Argue for Flexible, Risk-Based Approaches with Agencies In the evolving landscape of global regulatory frameworks, pharmacovigilance has emerged as a critical component in ensuring drug safety and efficacy. With challenges posed by diverse regulations, pharmaceutical companies must navigate complex approval pathways while adhering to agency expectations. This article serves as a comprehensive guide for regulatory affairs professionals, providing insights into the International Council for Harmonisation (ICH) guidelines and their implications for flexible, risk-based approaches to regulatory submissions. Regulatory Affairs Context Regulatory Affairs (RA) is a…

Lessons from Inspections Where ICH Expectations Were Not Fully Met Lessons from Inspections Where ICH Expectations Were Not Fully Met The International Council for Harmonisation (ICH) has developed guidelines aiming to streamline the drug development and approval processes globally, ensuring the safety, efficacy, and quality of pharmaceuticals. However, deviations from these guidelines can lead to significant regulatory challenges. This article provides a comprehensive regulatory explainer manual for professionals in Regulatory Affairs (RA), focusing on lessons learned from inspections where ICH expectations were not fully met. It covers regulatory context, legal basis, documentation expectations, review and approval workflow, and insights into…

Future Direction of ICH: Topics RA and Clinical Leaders Should Monitor Future Direction of ICH: Topics RA and Clinical Leaders Should Monitor Context The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) plays a fundamental role in the global harmonisation of drug development and approval processes. As regulatory affairs professionals navigate the evolving landscape of pharma and biotech industries, an understanding of ICH guidelines is essential. This article explores the regulatory expectations surrounding recent and future ICH initiatives, providing insight into how regulatory affairs (RA), clinical, chemistry, manufacturing, and controls (CMC), and labelling functions must…

Building an Internal ICH Compliance Checklist for Key Development Milestones Building an Internal ICH Compliance Checklist for Key Development Milestones As the biopharmaceutical industry continues to expand globally, ensuring compliance with International Council for Harmonisation (ICH) guidelines has become increasingly vital. This article outlines how Regulatory Affairs (RA) professionals can establish an effective internal ICH compliance checklist to enhance the development and approval of new pharmaceuticals, particularly concerning pharmacovigilance systems. Understanding the regulations and guidelines that govern drug development is crucial for minimizing risks and ensuring timely approvals in the US, EU, and UK. Regulatory Affairs Context Within the pharmaceutical…

How ICH Influences Digital, Decentralised and Innovative Trial Models How ICH Influences Digital, Decentralised and Innovative Trial Models The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) plays a pivotal role in shaping global regulatory compliance within the pharmaceutical and biotech sectors. This article outlines the significant influence of ICH guidelines on regulatory processes pertaining to digital, decentralised, and innovative trial models, with a focus on compliance across the US, UK, and EU regulatory landscapes. Context As the demand for more efficient and patient-centric clinical study designs grows, regulatory bodies require innovative methodologies that do…

Case Studies Showing ICH-Consistent vs Non-Consistent Development Paths Case Studies Showing ICH-Consistent vs Non-Consistent Development Paths This article provides an analysis of regulatory compliance in the context of ICH guidelines, emphasizing the differences between ICH-consistent and non-consistent development paths in drug approval processes. It serves as a manual for Regulatory Affairs professionals, particularly those in CMC and Labelling teams in the US, UK, and EU. Regulatory Affairs Context Regulatory Affairs (RA) plays a vital role in the pharmaceutical and biotech industries, particularly in ensuring compliance with the legal requirements set forth by healthcare authorities such as the FDA, EMA, and…

Working with QA to Align ICH, GxP and Corporate Quality Standards Working with QA to Align ICH, GxP and Corporate Quality Standards Context In the complex landscape of pharmaceutical development and approval pathways, the collaboration between Regulatory Affairs (RA) and Quality Assurance (QA) is paramount. The need to harmonize International Conference on Harmonisation (ICH) guidelines with corporate quality standards and Good Practices (GxP) is essential for ensuring compliance and successful market entry of drug products in the US, EU, and UK. This article aims to provide a comprehensive regulatory explainer manual addressing the implications of ICH on regulatory compliance consulting…

Common Misunderstandings About ICH That Slow Teams Down Common Misunderstandings About ICH That Slow Teams Down Regulatory Affairs Context The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) was established to bring together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of drug registration. In the realm of regulatory affairs, understanding ICH guidelines is critical as they serve as a bridge to harmonise standards across global regulatory frameworks, mainly the EMA, FDA, and MHRA. However, common misunderstandings surrounding these guidelines can hinder the efficiency of regulatory processes. Legal/Regulatory Basis ICH guidelines…

Using ICH Language in Briefing Documents and Meeting Packages Using ICH Language in Briefing Documents and Meeting Packages The integration of International Conference on Harmonisation (ICH) guidelines within the regulatory documentation landscape is crucial for achieving successful drug approval across multiple jurisdictions. This article serves as a comprehensive manual for Regulatory Affairs (RA), Chemistry, Manufacturing, and Controls (CMC), and Labelling teams in the pharmaceutical sector within the US, EU, and UK. We will elucidate relevant regulations, guidelines, and agency expectations, specifically focusing on the utilization of ICH language in briefing documents and meeting packages. Context In the ever-evolving pharmaceutical landscape,…

Making ICH a Living Part of RA Strategy Rather Than a One-Off Training Making ICH a Living Part of RA Strategy Rather Than a One-Off Training In the continuously evolving landscape of pharmaceutical and biotech industries, the integration of International Council for Harmonisation (ICH) guidelines into Regulatory Affairs (RA) strategy is essential. ICH represents a collaborative initiative aimed at standardizing regulations that govern drug development and approval processes across the US, EU, and Japan. A robust understanding of these guidelines not only facilitates compliance but also enhances the efficiency of regulatory submissions, ultimately expediting the path to market for novel…